Overview
Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss syndrome, is a rare systemic small- and medium-vessel vasculitis characterized by asthma, peripheral and tissue eosinophilia, and necrotizing granulomatous inflammation. It belongs to the group of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides, though only about 30-40% of patients are ANCA-positive (typically perinuclear ANCA targeting myeloperoxidase). EGPA affects multiple organ systems and typically progresses through three phases, though not all patients follow this sequence. The prodromal phase features allergic disease including asthma and allergic rhinitis or nasal polyposis. The eosinophilic phase involves marked peripheral blood eosinophilia and eosinophilic tissue infiltration, particularly affecting the lungs and gastrointestinal tract. The vasculitic phase involves systemic small-vessel vasculitis that can affect the heart, peripheral nerves, skin, kidneys, and gastrointestinal tract. Cardiac involvement (myocarditis, cardiomyopathy, pericarditis) is the leading cause of mortality. Peripheral neuropathy, particularly mononeuritis multiplex, is one of the most common manifestations. Skin lesions including purpura and nodules are frequently observed. Treatment depends on disease severity. Glucocorticoids are the cornerstone of therapy and are effective in many patients. For severe or refractory disease, immunosuppressive agents such as cyclophosphamide or azathioprine are used. Mepolizumab, an anti-interleukin-5 monoclonal antibody, has been approved specifically for EGPA and has shown efficacy in reducing relapses and allowing glucocorticoid tapering. Rituximab is also used in refractory cases. With appropriate treatment, many patients achieve remission, though relapses are common and long-term management is often required.
Clinical phenotype terms— hover any for plain English:
Multifactorial
Caused by a mix of several genes and environmental factors
Adult
Begins in adulthood (age 18 or older)
FDA & Trial Timeline
10 eventsAzienda Ospedaliero Universitaria di Cagliari — PHASE4
AstraZeneca — PHASE3
Fasenra: FDA approved
treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA)
Imperial College London — PHASE2
University Medical Center Groningen
NS Pharma, Inc. — PHASE2
Guangdong Hengrui Pharmaceutical Co., Ltd — PHASE2, PHASE3
GlaxoSmithKline — PHASE3
Assistance Publique - Hôpitaux de Paris — PHASE3
NUCALA: FDA approved
NUCALA prefilled autoinjector and single syringe device is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
2 availableFasenra
treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA)
NUCALA
NUCALA prefilled autoinjector and single syringe device is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).
Rare Disease Specialist
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Financial Resources
1 resourcesTravel Grants
No travel grants are currently matched to Eosinophilic granulomatosis with polyangiitis.
Community
No community posts yet. Be the first to share your experience with Eosinophilic granulomatosis with polyangiitis.
Start the conversation →Latest news about Eosinophilic granulomatosis with polyangiitis
No recent news articles for Eosinophilic granulomatosis with polyangiitis.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Eosinophilic granulomatosis with polyangiitis
What is Eosinophilic granulomatosis with polyangiitis?
Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss syndrome, is a rare systemic small- and medium-vessel vasculitis characterized by asthma, peripheral and tissue eosinophilia, and necrotizing granulomatous inflammation. It belongs to the group of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides, though only about 30-40% of patients are ANCA-positive (typically perinuclear ANCA targeting myeloperoxidase). EGPA affects multiple organ systems and typically progresses through three phases, though not all patients follow this sequence. The prod
How is Eosinophilic granulomatosis with polyangiitis inherited?
Eosinophilic granulomatosis with polyangiitis follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Eosinophilic granulomatosis with polyangiitis typically begin?
Typical onset of Eosinophilic granulomatosis with polyangiitis is adult. Age of onset can vary across affected individuals.
Are there clinical trials for Eosinophilic granulomatosis with polyangiitis?
Yes — 10 recruiting clinical trials are currently listed for Eosinophilic granulomatosis with polyangiitis on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Eosinophilic granulomatosis with polyangiitis?
25 specialists and care centers treating Eosinophilic granulomatosis with polyangiitis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.
What treatment and support options exist for Eosinophilic granulomatosis with polyangiitis?
1 patient support program are currently tracked on UniteRare for Eosinophilic granulomatosis with polyangiitis. See the treatments and support programs sections for copay assistance, eligibility, and contact details.